Expanding Access to Medications for Opioid Use Disorder Treatment Through Incentivized Continuing Education

J Contin Educ Health Prof. 2022 Jan 1;42(1):e102-e105. doi: 10.1097/CEH.0000000000000384.

Abstract

Introduction: Buprenorphine treatment for opioid use disorder (OUD) has positive outcomes including reducing opioid-related morbidity and mortality. In March 2018, 58 of 102 counties in Illinois lacked access to medication for OUD.

Methods: Rush University created a fellowship training program with financial incentives to help expand buprenorphine treatment in Illinois. Fellows first completed an online waiver course, then attended an in-person intensive training weekend, and finally participated in a 9-month webinar series. Demographic and prescribing data were collected from fellows, as well as a comparison group of providers outside the fellowship who only completed a waiver training.

Results: At the fellowship's end, 31 of 37 fellows (84%) reported they were actively prescribing buprenorphine. Of the 23 fellows who were not prescribing at the fellowship's beginning, 17 (74%) initiated prescribing by the end. Among the 16 nonfellowship subjects who only completed a waiver training, just two (13%) reported they were prescribing buprenorphine at the study period's end.

Discussion: Our study indicates that providers need more training beyond the waiver to initiate buprenorphine prescribing. When resources are available to address a health crisis such as OUD, this model offers an innovative mechanism for delivering continuing medical education that produces outcomes quickly.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Buprenorphine* / therapeutic use
  • Education, Continuing
  • Health Services Accessibility
  • Humans
  • Opiate Substitution Treatment
  • Opioid-Related Disorders* / drug therapy

Substances

  • Buprenorphine